• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

脑脓肿治疗期间奥希替尼诱发心力衰竭与甲硝唑诱发脑病同时发生:1例罕见病例报告

Concurrent Onset of Osimertinib-Induced Heart Failure and Metronidazole-Induced Encephalopathy During Brain Abscess Treatment: A Report of a Rare Case.

作者信息

Mikami Emi, Hashimoto Kosuke, Kaira Kyoichi, Mouri Atsuto, Miura Yu, Shiono Ayako, Yamaguchi Ou, Imai Hisao, Kagamu Hiroshi

机构信息

Clinical Training Center, Saitama Medical University International Medical Center, Hidaka, JPN.

Respiratory Medicine, Saitama Medical University International Medical Center, Hidaka, JPN.

出版信息

Cureus. 2024 Dec 4;16(12):e75079. doi: 10.7759/cureus.75079. eCollection 2024 Dec.

DOI:10.7759/cureus.75079
PMID:39759665
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11698534/
Abstract

We report a rare case of concurrent onset of osimertinib-induced heart failure and metronidazole-induced encephalopathy during treatment of a brain abscess. A 78-year-old female with lung adenocarcinoma presented with neurological symptoms and was diagnosed with a brain abscess. During treatment, she developed heart failure and encephalopathy, linked to osimertinib and metronidazole, respectively. Following the discontinuation of these drugs, her symptoms gradually improved. This case underscores the need for careful monitoring of adverse drug reactions, especially in patients with significant weight loss. Regular cardiac and neurological assessments are recommended to promptly identify and manage such events.

摘要

我们报告了一例在脑脓肿治疗期间同时发生奥希替尼诱发的心力衰竭和甲硝唑诱发的脑病的罕见病例。一名78岁的肺腺癌女性出现神经症状,被诊断为脑脓肿。在治疗过程中,她分别出现了与奥希替尼和甲硝唑相关的心力衰竭和脑病。停用这些药物后,她的症状逐渐改善。该病例强调了仔细监测药物不良反应的必要性,尤其是在体重显著减轻的患者中。建议定期进行心脏和神经评估,以便及时识别和处理此类事件。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31aa/11698534/bf864679793c/cureus-0016-00000075079-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31aa/11698534/8ad2515638d3/cureus-0016-00000075079-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31aa/11698534/bf864679793c/cureus-0016-00000075079-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31aa/11698534/8ad2515638d3/cureus-0016-00000075079-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31aa/11698534/bf864679793c/cureus-0016-00000075079-i02.jpg

相似文献

1
Concurrent Onset of Osimertinib-Induced Heart Failure and Metronidazole-Induced Encephalopathy During Brain Abscess Treatment: A Report of a Rare Case.脑脓肿治疗期间奥希替尼诱发心力衰竭与甲硝唑诱发脑病同时发生:1例罕见病例报告
Cureus. 2024 Dec 4;16(12):e75079. doi: 10.7759/cureus.75079. eCollection 2024 Dec.
2
Osimertinib-induced cardiac failure with QT prolongation and torsade de pointes in a patient with advanced pulmonary adenocarcinoma.奥希替尼诱发一名晚期肺腺癌患者出现心力衰竭伴QT间期延长及尖端扭转型室速。
Int Cancer Conf J. 2020 Oct 15;10(1):68-71. doi: 10.1007/s13691-020-00450-2. eCollection 2021 Jan.
3
Atypical metronidazole-induced encephalopathy in anaerobic brain abscess.厌氧性脑脓肿中不典型的甲硝唑诱发的脑病
J Korean Neurosurg Soc. 2012 Sep;52(3):273-6. doi: 10.3340/jkns.2012.52.3.273. Epub 2012 Sep 30.
4
[Metronidazole-Induced Encephalopathy during Brain Abscess Treatment:Two Case Reports].[脑脓肿治疗期间甲硝唑诱发的脑病:两例报告]
No Shinkei Geka. 2015 Oct;43(10):927-32. doi: 10.11477/mf.1436203151.
5
Osimertinib induced cardiac failure and QT-prolongation in a patient with advanced pulmonary adenocarcinoma.奥希替尼致晚期肺腺癌患者心力衰竭及 QT 间期延长。
J Oncol Pharm Pract. 2022 Jun;28(4):989-994. doi: 10.1177/10781552211073823. Epub 2022 Jan 17.
6
Successful treatment with afatinib following the failure of osimertinib rechallenge with osimertinib-induced interstitial lung disease: A case report.奥希替尼因奥希替尼诱导的间质性肺病再次挑战失败后使用阿法替尼成功治疗:一例报告
Respir Med Case Rep. 2021 Jun 23;33:101450. doi: 10.1016/j.rmcr.2021.101450. eCollection 2021.
7
Metronidazole-induced encephalopathy in a patient with pyogenic spondylitis: a case report.甲硝唑诱发的化脓性脊柱炎患者脑病:一例报告
BMC Musculoskelet Disord. 2018 Sep 18;19(1):336. doi: 10.1186/s12891-018-2255-8.
8
[A case of irreversible metronidazole encephalopathy during liver abscess treatment].[肝脓肿治疗期间不可逆性甲硝唑脑病1例]
Nihon Shokakibyo Gakkai Zasshi. 2023;120(10):858-867. doi: 10.11405/nisshoshi.120.858.
9
Life-threatening interstitial lung disease with adjuvant osimertinib after complete resection of non-small cell lung cancer: a case report.非小细胞肺癌完全切除术后使用奥希替尼辅助治疗导致危及生命的间质性肺疾病:一例报告
AME Case Rep. 2025 Apr 14;9:56. doi: 10.21037/acr-24-203. eCollection 2025.
10
A case with reversible neurotoxicity induced by metronidazole.一例由甲硝唑引起的可逆性神经毒性病例。
Ideggyogy Sz. 2017 Nov 30;70(11-12):429-432. doi: 10.18071/isz.70.0429.

本文引用的文献

1
Frequency and Risk Factor Analysis for Metronidazole-Associated Neurologic Adverse Events.甲硝唑相关神经系统不良事件的频率及危险因素分析。
J Gen Intern Med. 2024 May;39(6):912-920. doi: 10.1007/s11606-023-08566-w. Epub 2023 Dec 13.
2
Pharmacokinetic and dose-finding study of osimertinib in patients with impaired renal function and low body weight.在肾功能受损和低体重患者中奥希替尼的药代动力学和剂量探索研究。
Cancer Sci. 2023 May;114(5):2087-2097. doi: 10.1111/cas.15736. Epub 2023 Feb 14.
3
Cardiac Adverse Events in -Mutated Non-Small Cell Lung Cancer Treated With Osimertinib.
奥希替尼治疗携带EGFR突变的非小细胞肺癌患者的心脏不良事件
JACC CardioOncol. 2020 Mar 17;2(1):1-10. doi: 10.1016/j.jaccao.2020.02.003. eCollection 2020 Mar.
4
Cardiac Safety of Osimertinib: A Review of Data.奥希替尼的心脏安全性:数据回顾。
J Clin Oncol. 2021 Feb 1;39(4):328-337. doi: 10.1200/JCO.20.01171. Epub 2020 Dec 23.
5
Metronidazole-induced encephalopathy: a systematic review.甲硝唑诱导的脑病:系统评价。
J Neurol. 2020 Jan;267(1):1-13. doi: 10.1007/s00415-018-9147-6. Epub 2018 Dec 7.
6
Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 1, drugs administered intravenously).心力衰竭患者药物的临床药代动力学:更新(第 1 部分,静脉内给药的药物)。
Clin Pharmacokinet. 2013 Mar;52(3):169-85. doi: 10.1007/s40262-012-0029-2.
7
Impact of obesity on drug metabolism and elimination in adults and children.肥胖对成人和儿童药物代谢和消除的影响。
Clin Pharmacokinet. 2012 May 1;51(5):277-304. doi: 10.2165/11599410-000000000-00000.
8
Clinical pharmacokinetics of metronidazole.甲硝唑的临床药代动力学
Clin Pharmacokinet. 1983 Jan-Feb;8(1):43-62. doi: 10.2165/00003088-198308010-00003.
9
Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives.甲硝唑及其他硝基咪唑类抗感染药物的临床药代动力学
Clin Pharmacokinet. 1992 Nov;23(5):328-64. doi: 10.2165/00003088-199223050-00002.